|
|
|
|
|
|
|
|
|
|
Note: speaks about PFS vs OS (progression free survival; overall survival); PLD and Trabectedin (Yondelis) study (Monk); ICON4 and more
Monday, June 28, 2010
Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough? -- Cannistra 28 (19): 3101 -- Journal of Clinical Oncology
Note: speaks about PFS vs OS (progression free survival; overall survival); PLD and Trabectedin (Yondelis) study (Monk); ICON4 and more
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.